BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36394299)

  • 21. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
    Asano R; Watanabe Y; Kawaguchi H; Fukazawa H; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Biol Chem; 2007 Sep; 282(38):27659-65. PubMed ID: 17644522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
    Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
    MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
    Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
    J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients.
    Schaafsma MR; Falkenburg JH; Landegent JE; Duinkerken N; Osanto S; Ralph P; Kaushansky K; Wagemaker G; Van Damme J; Willemze R
    Blood; 1991 Oct; 78(8):1981-7. PubMed ID: 1912580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
    Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
    J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
    Reichardt VL; Milazzo C; Brugger W; Einsele H; Kanz L; Brossart P
    Haematologica; 2003 Oct; 88(10):1139-49. PubMed ID: 14555310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.
    Zou J; Chen D; Zong Y; Ye S; Tang J; Meng H; An G; Zhang X; Yang L
    Cancer Sci; 2015 May; 106(5):512-21. PubMed ID: 25664501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
    Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
    Br J Haematol; 2000 Mar; 108(4):805-16. PubMed ID: 10792287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The eIg technology to generate Ig-like bispecific antibodies.
    Kühl L; Aschmoneit N; Kontermann RE; Seifert O
    MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective correlation of interferon-gamma, tumour necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor with immunoglobulin G1 and immunoglobulin G3 subclass antibody in leprosy.
    Hussain R; Kifayet A; Dojki M; Dockrell HM
    Immunology; 1999 Oct; 98(2):238-43. PubMed ID: 10540222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy of NOD mice with bone marrow-derived dendritic cells.
    Feili-Hariri M; Dong X; Alber SM; Watkins SC; Salter RD; Morel PA
    Diabetes; 1999 Dec; 48(12):2300-8. PubMed ID: 10580417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy.
    Xie F; Zhang L; Shi S; Zheng A; Di J; Jin S; Miao X; Wu F; Chen X; Zhang Y; Wei X; Xu Y
    MAbs; 2022; 14(1):2115205. PubMed ID: 36041060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody.
    Chatterjee SK; Tripathi PK; Chakraborty M; Yannelli J; Wang H; Foon KA; Maier CC; Blalock JE; Bhattacharya-Chatterjee M
    Cancer Res; 1998 Mar; 58(6):1217-24. PubMed ID: 9515808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idiotype antibody conjugates.
    Gravelle M; Ochi A
    J Immunol; 1989 Jun; 142(11):4079-84. PubMed ID: 2523940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T cell functions in granulocyte/macrophage colony-stimulating factor deficient mice.
    Wada H; Noguchi Y; Marino MW; Dunn AR; Old LJ
    Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12557-61. PubMed ID: 9356488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
    Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
    J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.